The anti-obesity effects of GEP could be attributed to its suppression of these lipogenic genes; however, 1% GEP appeared to increase SREBP1c levels but decreased FAS and SCD1 levels, suggesting that the lipogenesis inhibiting activities of GEP may also be linked to other regulatory mechanisms. This evidence concerns the gene SCD and obesity disorder.